Jyong Biotech (NASDAQ:MENS) Reaches New 52-Week Low - Here's Why

Key Points

• Jyong Biotech hit a new 52-week low, trading as low as $2.81 and last at $2.92 (vs. a prior close of $15.40) on heavy volume of about 3.19 million shares, representing an ~81% decline noted by the report.
• Analysts maintain a negative view — Weiss Ratings reiterated a "sell (e+)" and MarketBeat shows a consensus rating of "Sell," while the stock sits far below its 50-day moving average of $39.02.
• Institutional interest was minimal: BNP Paribas Financial Markets bought a small new position of 1,698 shares (about $67,000) in the third quarter despite the weak price action.

Jyong Biotech Ltd. (NASDAQ:MENS - Get Free Report)'s share price hit a new 52-week low during mid-day trading on Wednesday . The company traded as low as $2.81 and last traded at $2.92, with a volume of 3192141 shares changing hands. The stock had previously closed at $15.40.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a "sell (e+)" rating on shares of Jyong Biotech in a research report on Wednesday, October 8th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Jyong Biotech has a consensus rating of "Sell".

Jyong Biotech Trading Down 81.0%

The company has a fifty day moving average of $39.02.

Institutional Investors Weigh In On Jyong Biotech

An institutional investor recently bought a new position in Jyong Biotech stock. BNP Paribas Financial Markets purchased a new position in shares of Jyong Biotech Ltd. (NASDAQ:MENS - Free Report) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 1,698 shares of the company's stock, valued at approximately $67,000.

About Jyong Biotech

OUR MISSION We endeavor to develop and supply first-class innovative drugs to meet our customers' health needs. We seek to be a valuable business organization that is held in high esteem by the public. We are a science-driven biotechnology company based in Taiwan and are committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU, and Asia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.